<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04881955</url>
  </required_header>
  <id_info>
    <org_study_id>EBS-101-HV-103</org_study_id>
    <nct_id>NCT04881955</nct_id>
  </id_info>
  <brief_title>Study of the Absorption, Metabolism, and Excretion of [14C]-Ecopipam in Healthy Male Subjects</brief_title>
  <official_title>A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Ecopipam Following a Single Oral Capsule Dose in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emalex Biosciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emalex Biosciences Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, single-center (United Kingdom), open-label, nonrandomized, single-dose study in&#xD;
      healthy adult male subjects to assess the absorption, metabolism, and excretion of&#xD;
      [14C]-Ecopipam in Healthy Male Subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a Phase 1, open-label, nonrandomized, single-dose study in healthy male&#xD;
      subjects. Potential subjects will be screened to assess their eligibility to enter the study&#xD;
      within 29 days prior to dose administration. Subjects will be admitted into the clinical&#xD;
      research unit (CRU) on Day -1 and be confined to the CRU until at least Day 8 (Discharge). On&#xD;
      Day 1, subjects will receive a single oral dose of 200 mg ecopipam HCl containing&#xD;
      approximately 88.5 µCi of [14C]-ecopipam HCl. Subjects will be discharged when the following&#xD;
      discharge criteria are met:&#xD;
&#xD;
        -  plasma radioactivity levels below the limit of quantitation for 2 consecutive&#xD;
           collections;&#xD;
&#xD;
        -  ≥ 90% mass balance recovery; and&#xD;
&#xD;
        -  ≤ 1% of the total radioactive dose is recovered in combined excreta (urine and feces) in&#xD;
           2 consecutive 24-hour periods in which collections occur. If discharge criteria are not&#xD;
           met on Day 8, subjects will remain in the CRU and additional 24-hour collections (blood,&#xD;
           urine, and feces) for total radioactivity will continue until these criteria are met, up&#xD;
           to a maximum of Day 15.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of radioactivity excreted in urine (Aeu)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 18 urine samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative radioactivity excreted in urine (Aeu)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 18 urine samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of radioactivity excreted in feces (Aef)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 16 feces samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative radioactivity excreted in feces (Aef)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 16 feces samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of dose excreted in urine (feu)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 18 urine samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of dose excreted in feces (fef)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 16 feces samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative dose excreted in urine (feu)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 18 urine samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative dose excreted in feces (fef)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 16 feces samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of total radioactivity in total excreta (feces + urine)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 18 urine and feces samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) from time zero extrapolated to infinity (AUC0-inf)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 28 blood samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time zero to the last quantifiable concentration (AUC0 last)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 28 blood samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) radioactivity feces + urine)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 28 blood samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Cmax (Tmax)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 28 blood samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life (t1/2)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 28 blood samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total clearance (CL/F; ecopipam only)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 28 blood samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vz/F; ecopipam only)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 28 blood samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of plasma ecopipam concentration relative to AUC0-inf of plasma total radioactivity (AUC0-inf Plasma ecopipam/Total Radioactivity Ratio)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 28 blood samples will be collected at the indicated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of whole blood total radioactivity to AUC0-inf of plasma total radioactivity (AUC0 inf Blood/Plasma Ratio)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 28 blood samples will be collected at the indicated time points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of ecopipam and metabolites to total radioactivity in plasma</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 28 blood samples will be collected at the indicated time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of ecopipam and metabolites to total radioactivity in urine and faeces</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Up to 18 urine and faeces samples will be collected at the indicated time points</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>[14C]-Ecopipam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral capsule dose of 200 mg ecopipam HCl containing approximately 88.5 µCi of [14C]-ecopipam HCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-Ecopipam</intervention_name>
    <description>[14C]-Ecopipam</description>
    <arm_group_label>[14C]-Ecopipam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males of any race between 35 and 55 years of age&#xD;
&#xD;
          -  Body mass index between 18.0 and 30.0 kg/m2&#xD;
&#xD;
          -  In good health&#xD;
&#xD;
          -  Males will agree to use contraception&#xD;
&#xD;
          -  Able to comprehend and sign an informed consent form&#xD;
&#xD;
          -  History of a minimum of 1 bowel movement per day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of significant medical illness&#xD;
&#xD;
          -  History of clinically significant drug allergy&#xD;
&#xD;
          -  History of a seizure disorder, not including infantile seizures&#xD;
&#xD;
          -  History of stomach or intestinal surgery that would potentially alter absorption&#xD;
             and/or excretion of orally administered drugs&#xD;
&#xD;
          -  Clinically significant medical treatment within 8 weeks or infection treatment within&#xD;
             4 weeks of dosing&#xD;
&#xD;
          -  Clinically significant ECG abnormality&#xD;
&#xD;
          -  History of alcoholism or drug/chemical abuse within the previous 2 years or positive&#xD;
             screening test&#xD;
&#xD;
          -  Significant alcohol consumption&#xD;
&#xD;
          -  Positive hepatitis panel and/or positive human immunodeficiency virus test&#xD;
&#xD;
          -  Use of prohibited prescription, over-the-counter medications or natural health&#xD;
             products&#xD;
&#xD;
          -  Use of tobacco or nicotine-containing products within 3 months prior to Check-in or&#xD;
             positive screening test&#xD;
&#xD;
          -  Receipt of blood products within 2 months prior to Check in&#xD;
&#xD;
          -  Recent donation of blood, plasma, or platelets prior to Screening&#xD;
&#xD;
          -  Exposure to significant diagnostic, therapeutic or employment in a job requiring&#xD;
             radiation exposure monitoring within 12 months prior to Check-in&#xD;
&#xD;
          -  Evidence or history of active suicidal thoughts in the previous 5 years or have any&#xD;
             lifetime history of a suicide attempt&#xD;
&#xD;
          -  Not suitable for study in the opinion of the Principal Investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emalex Biosciences</last_name>
    <phone>312.847.1340</phone>
    <email>emalex@emalexbiosciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Ltd.</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Brooks, MBChB</last_name>
      <phone>0113-301-3521</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ecopipam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

